September 15, 2025

Is Cure Finally Achievable in Multiple Myeloma?

After decades of incremental progress in the treatment of multiple myeloma, survival has increased from 3 years in the late 1990s to between 8 and 10 years today.1 Could cure for a disease that kills ...

The ASCO Post

September 15, 2025

Pilot study tests ALS drug to treat chemo brain in cancer patients

A first-of-its-kind study tests ALS drug riluzole to restore cognitive function in cancer survivors.

UCI Health

September 12, 2025

Using Electricity, Not Heat, to Ablate Tumors and Reinvigorate the Immune System

Using pulsed electric field ablation for resectable tumors helps not only kill the cancerous cells but might reinvigorate a patient’s immune system to fight back against their cancers.

Roswell Park Comprehensive Cancer Center

September 10, 2025

Do the Results From CARTITUDE-1 Represent a Cure for Patients With Multiple Myeloma? We Need Longer Follow-Up to Know for Sure

The results of the CARTITUDE-1 clinical trial demonstrate outstanding and unprecedented long-term efficacy with ciltacabtagene autoleucel, a B-cell maturation antigen–directed chimeric antigen recepto...

The ASCO Post

September 10, 2025

The Implications of the Results From CARTITUDE-1 for Future Research and Care in Multiple Myeloma

The results from the CARTITUDE-1 study showed the remarkable efficacy of ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy, when use...

The ASCO Post

September 10, 2025

Update to ASCO Living Guideline for NSCLC Without Driver Alterations Includes First Comparison of Immunotherapy Options

ASCO has issued a new update to its living guideline regarding therapy for stage IV non–small cell lung cancer (NSCLC) without driver alterations, based on results of three studies published recently....

The ASCO Post

September 10, 2025

‘A Playbook for Best Practices’: ASCO and COA Release Updated Oncology Medical Home Standards

ASCO and the Community Oncology Alliance (COA) have released updated standards for its Oncology Medical Home (OMH) certification program, which were initially codified and published in 2021.1 The 2021...

The ASCO Post

September 10, 2025

Overcoming the Challenges of Safely Using Opioids to Treat Patients With Chronic Cancer-Related Pain

Research has shown that pain is among the most commonly experienced and feared aspects of a cancer diagnosis.1 It’s easy to understand why. In fact, cancer-related pain is so ubiquitous, between 20% a...

The ASCO Post

September 10, 2025

The Future of Cell Therapy: Optimizing the CAR to the Disease in B-Cell Malignancies

Explore the evolution of therapies for B-cell malignancies and the potential of dual-targeted CAR T-cell approaches to enhance patient outcomes. - Dr. Shah

The ASCO Post